Patent application number | Description | Published |
20120134933 | USE OF HIGH-DOSES OF MONOMERIC CONTRAST MEDIUM CONTAINING IODINE IN X-RAY DIAGNOSTICS, IN PARTICULAR IN INTERVENTIONAL X-RAY DIAGNOSTICS AND IN RADIATION THERAPY ASSISTED BY CONTRAST MEDIA CONTAINING IODINE - The invention relates to a diagnostic or therapeutic composition comprising a monomeric X-ray contrast medium containing iodine, in particular iopromide, for use in an X-ray assisted diagnosis or therapy and for the use of high doses of an X-ray contrast medium given to a patient, in particular patients with restricted kidney function. | 05-31-2012 |
20130066055 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF - The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 03-14-2013 |
20130122024 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF - The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target mesothelin, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 05-16-2013 |
20130157960 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF - The present application relates to novel derivatives of monomethylauristatin F, to processes for preparing these derivatives, to the use of these derivatives for treating and/or preventing diseases, and also to the use of these derivatives for preparing medicaments for treating and/or preventing diseases, more particularly hyperproliferative and/or angiogenic disorders such as, for example, cancerous disorders. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 06-20-2013 |
20130261064 | N-CARBOXYALKYL-AURISTATIN AND THE USE THEREOF - The present application relates to new derivatives of monomethylauristatin F, substituted on the N terminus by a carboxyalkyl group, processes for preparing these derivatives, their use for the treatment and/or prevention of diseases and to produce medication for the treatment and/or prevention of diseases, particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments can occur as monotherapies or in combination with other medication or further therapeutic measures. | 10-03-2013 |
20140127240 | Novel Binder-Drug Conjugates (ADCs) and Use of Same - The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures. | 05-08-2014 |
20140322220 | Anti-FGFR2 Antibodies and Uses Thereof - The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 10-30-2014 |
20150023989 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF - The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures. | 01-22-2015 |
20150030618 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF - The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 01-29-2015 |